LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

NCT07312422 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
PD-L1
PD-1 Inhibitor
LDRT
Proterizumab

Interventions

RADIATION: Low-dose Radiotherapy
BIOLOGICAL: Pucotenlimab
DRUG: AG regimen
DRUG: FOLFIRINOX regimen

Sponsor

Zhejiang Provincial People's Hospital